AR-C69931MX is a potent and selective antagonist of the P2Y12 receptor, which plays a key role in platelet activation and aggregation. It is primarily used in research settings to study platelet function and the mechanisms of thrombosis. By inhibiting the P2Y12 receptor, AR-C69931MX prevents adenosine diphosphate (ADP)-induced platelet activation, making it a valuable tool for understanding the role of ADP pathways in hemostasis and clot formation. Its application extends to experimental models of cardiovascular disease, where it helps assess the efficacy and mechanisms of antiplatelet therapies. Due to its high selectivity and reversible action, it is also used to compare the pharmacological profiles of other antiplatelet agents, including thienopyridines like clopidogrel. AR-C69931MX is not used clinically but supports the development and testing of new antithrombotic drugs.